OGN Stock Recent News
OGN LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151559&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Organon & Co. ("Organon" or "the Company") (NYSE:OGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Organon securities between October 31, 2024 and April 30, 2025, both dates inclusive (the "Class Period").
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151532&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151527&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.
NEW YORK and NEW ORLEANS, June 03, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151519&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives.
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151500&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE:OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action.
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151475&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.